Beneficient Registers 71M Shares for Resale Amidst Yorkville Funding
Ticker: BENFW · Form: S-1 · Filed: Dec 23, 2025 · CIK: 1775734
Sentiment: bearish
Topics: S-1 Filing, Equity Offering, Dilution Risk, Standby Equity Purchase Agreement, Preferred Stock Conversion, Reverse Stock Split, Nasdaq Capital Market
TL;DR
**Beneficient's massive share registration and ongoing Yorkville funding signal significant dilution risk; avoid BENF until capital structure stabilizes.**
AI Summary
Beneficient (BENFW) filed an S-1 on December 23, 2025, to register the resale of up to 71,017,840 shares of Class A common stock by various selling holders. This includes 64,371,217 shares potentially issued to Yorkville under a Standby Equity Purchase Agreement (SEPA) for up to $250 million, of which $9.3 million has already been utilized for 613,972 shares. The company also registered 165,674 Warrant Shares for Yorkville at an exercise price of $21.04, and shares convertible from various Series B preferred stock issued to investors like Mendoza Ventures, Interest Solutions, Convergency Partners, 8F Fund, Pulse Pioneer Fund, Cork & Vines Fund I, and Mendoza Ventures Growth Fund III. A significant event was the reverse stock split on December 15, 2025, which reduced authorized Class A common stock from 5,000,000,000 to 625,000,000 shares. As of December 19, 2025, the Class A common stock closed at $6.85 per share, and public warrants (BENFW) at $0.0137. The company will not receive any proceeds from the selling holders' sales.
Why It Matters
This S-1 filing signals a significant potential dilution for existing Beneficient shareholders, as up to 71,017,840 shares of Class A common stock are being registered for resale. The ongoing reliance on the Standby Equity Purchase Agreement (SEPA) with Yorkville for up to $240.7 million in remaining funding, coupled with the recent reverse stock split, indicates a company actively seeking capital, potentially at the expense of per-share value. Investors should be wary of the substantial overhang from these registered shares, which could depress the stock price (BENF) and public warrants (BENFW) as selling holders liquidate their positions. The company's 'controlled company' status also limits corporate governance oversight compared to peers.
Risk Assessment
Risk Level: high — The registration of 71,017,840 shares for resale, representing a substantial portion of the company's Class A common stock, creates significant potential for dilution. The company's ability to issue up to 36,995,521 shares under Pricing Option 1 (72.8% of outstanding shares) or 36,232,726 shares under Pricing Option 2 (72.4% of outstanding shares) to Yorkville under the SEPA, based on a $6.85 closing price on December 19, 2025, indicates a high risk of downward pressure on the stock price.
Analyst Insight
Investors should exercise extreme caution and consider avoiding Beneficient (BENF) shares due to the substantial potential for dilution from the 71,017,840 registered shares. Monitor the volume and pricing of sales by the Selling Holders, particularly Yorkville, as significant selling pressure could further depress the stock price. Existing shareholders should evaluate their position given the high risk of value erosion.
Financial Highlights
- debt To Equity
- N/A
- revenue
- $N/A
- operating Margin
- N/A
- total Assets
- $N/A
- total Debt
- $N/A
- net Income
- $N/A
- eps
- $N/A
- gross Margin
- N/A
- cash Position
- $N/A
- revenue Growth
- N/A
Executive Compensation
| Name | Title | Total Compensation |
|---|---|---|
| N/A | N/A | $N/A |
Key Numbers
- 71,017,840 — Shares of Class A common stock (Total shares registered for resale by Selling Holders)
- $250 million — Maximum amount under SEPA (Total potential funding from Yorkville via Standby Equity Purchase Agreement)
- $9.3 million — Amount utilized under SEPA (Aggregate price for 613,972 shares sold to Yorkville under SEPA)
- $240.7 million — Remaining available under SEPA (Unused portion of the Standby Equity Purchase Agreement with Yorkville)
- 64,371,217 — SEPA Shares (Shares of Class A common stock that may be issued and sold to Yorkville under the SEPA)
- 165,674 — Warrant Shares (Shares of Class A common stock issuable upon exercise of warrants held by Yorkville)
- $21.04 — Warrant exercise price (Exercise price for warrants held by Yorkville)
- 625,000,000 — Authorized Class A common stock (Number of authorized shares after the December 15, 2025 reverse stock split)
- $6.85 — Class A common stock closing price (Last reported sales price on December 19, 2025)
- $0.0137 — Public Warrants closing price (Last reported sales price on December 19, 2025)
Key Players & Entities
- Beneficient (company) — Registrant and issuer of Class A common stock
- Yorkville (company) — Selling Holder and counterparty to Standby Equity Purchase Agreement (SEPA) and Purchase Agreement for Convertible Debentures and Warrants
- Mendoza Ventures Pre-Seed Fund II LP (company) — Selling Holder of Series B-2 Resettable Convertible Preferred Stock
- Interest Solutions, LLC (company) — Selling Holder of Series B-3 Resettable Convertible Preferred Stock
- Convergency Partners, LLC (company) — Selling Holder of Series B-4 Resettable Convertible Preferred Stock
- Maxim Partners LLC (company) — Selling Holder of Maxim Shares
- Mendota Financial Company, LLC (company) — Selling Holder of Vendor Shares
- 8F Fund, LP (company) — Selling Holder of Series B-5 Resettable Convertible Preferred Stock
- Pulse Pioneer Fund, LP (company) — Selling Holder of Series B-6 Resettable Convertible Preferred Stock
- Cork & Vines Fund I, LP (company) — Selling Holder of Series B-7 Resettable Convertible Preferred Stock
FAQ
What is the purpose of Beneficient's S-1 filing on December 23, 2025?
Beneficient's S-1 filing on December 23, 2025, is to register for resale up to 71,017,840 shares of Class A common stock held by various selling holders, including shares potentially issued to Yorkville under a Standby Equity Purchase Agreement and shares convertible from preferred stock.
How much funding has Beneficient received from Yorkville under the SEPA to date?
As of the filing date, Beneficient has offered and sold 613,972 shares of Class A common stock to Yorkville under the SEPA for an aggregate price of approximately $9.3 million.
What is the remaining amount available to Beneficient under the Standby Equity Purchase Agreement with Yorkville?
Approximately $240.7 million remains available to Beneficient under the Standby Equity Purchase Agreement (SEPA) with Yorkville.
What was the impact of Beneficient's reverse stock split on its authorized shares?
In connection with Beneficient's reverse stock split effected on December 15, 2025, the number of authorized shares of Class A common stock was reduced from 5,000,000,000 to 625,000,000.
Who are some of the key selling holders identified in Beneficient's S-1 filing?
Key selling holders identified in Beneficient's S-1 filing include Yorkville, Mendoza Ventures Pre-Seed Fund II LP, Interest Solutions, LLC, Convergency Partners, LLC, Maxim Partners LLC, Mendota Financial Company, LLC, 8F Fund, LP, Pulse Pioneer Fund, LP, Cork & Vines Fund I, LP, and Mendoza Ventures Growth Fund III, LP.
What is the exercise price for the warrants issued to Yorkville by Beneficient?
The warrants issued to Yorkville by Beneficient are exercisable into 165,674 shares of Class A common stock at an exercise price of $21.04 per share.
Will Beneficient receive any proceeds from the sale of shares by the Selling Holders?
No, Beneficient will not receive any of the proceeds from the sale by the Selling Holders of the Offered Securities.
What was the closing price of Beneficient's Class A common stock on December 19, 2025?
On December 19, 2025, the last reported sales price of Beneficient's Class A common stock (BENF) was $6.85 per share.
Why is Beneficient considered a 'controlled company' according to the Nasdaq Listing Rules?
Beneficient is considered a 'controlled company' because holders of its Class B common stock have the right to elect a majority of the Company's directors, as outlined in a stockholders agreement.
What are the two pricing options for Beneficient to sell shares to Yorkville under the SEPA?
Under the SEPA, Beneficient can sell shares to Yorkville at 95% of the daily VWAP during the Option 1 Pricing Period, or at 97% of the lowest VWAP during any three consecutive trading days in the Option 2 Pricing Period.
Risk Factors
- Reliance on Standby Equity Purchase Agreement (SEPA) [high — financial]: The company's ability to raise significant capital is heavily dependent on the SEPA with Yorkville, which allows for up to $250 million. As of the filing, $9.3 million has been utilized, leaving $240.7 million potentially available. However, the issuance of up to 64,371,217 shares under this agreement could lead to substantial dilution for existing shareholders.
- Volatility of Class A Common Stock and Public Warrants [medium — market]: The Class A common stock closed at $6.85 per share and public warrants (BENFW) at $0.0137 on December 19, 2025. This low valuation for warrants suggests significant market skepticism about the company's future prospects or the likelihood of warrant exercise.
- Significant Dilution from SEPA and Preferred Stock Conversions [high — financial]: The registration of 71,017,840 shares for resale, including those from the SEPA and convertible preferred stock, indicates a substantial potential increase in the total number of outstanding shares. This could significantly dilute the ownership percentage of current shareholders.
- Registration of Resale Shares [medium — regulatory]: The S-1 filing is for the resale of shares by existing holders, not for raising new capital for the company. This means the company does not receive proceeds from these sales, but the increased supply of shares in the market could pressure prices.
- Reverse Stock Split Impact [low — financial]: A reverse stock split on December 15, 2025, reduced authorized Class A common stock from 5,000,000,000 to 625,000,000 shares. While this may improve per-share metrics, it does not fundamentally alter the company's financial condition or market capitalization.
Industry Context
Beneficient operates in a sector that often relies on complex financial instruments and strategic partnerships for growth. The company's reliance on equity financing, particularly through agreements like the SEPA, is common in industries requiring substantial capital investment. The competitive landscape likely involves other companies seeking similar funding mechanisms and facing similar market pressures.
Regulatory Implications
The S-1 filing itself is a standard SEC requirement for the resale of securities. The significant number of shares being registered for resale could attract scrutiny regarding market impact and potential price manipulation. Compliance with ongoing reporting requirements under the Securities Exchange Act of 1934 will be crucial.
What Investors Should Do
- Monitor SEPA Utilization and Dilution
- Evaluate Warrant Exercise Likelihood
- Analyze Post-Filing Share Supply
- Scrutinize Financial Health (when available)
Key Dates
- 2025-12-23: S-1 Filing for Resale of Shares — Registered up to 71,017,840 shares for resale by selling holders, including potential SEPA shares and convertible securities.
- 2025-12-15: Reverse Stock Split — Reduced authorized Class A common stock from 5,000,000,000 to 625,000,000 shares.
- 2025-12-19: Class A Common Stock and Public Warrants Closing Prices — Class A common stock closed at $6.85, and public warrants (BENFW) at $0.0137, indicating market sentiment and valuation.
Glossary
- Standby Equity Purchase Agreement (SEPA)
- An agreement where an investor commits to purchase a certain amount of a company's stock over a period, at the company's discretion, usually at a discount to market price. (Beneficient has a SEPA with Yorkville for up to $250 million, representing a key potential source of future funding, but also a source of significant dilution.)
- Reverse Stock Split
- A corporate action where a company reduces the number of its outstanding shares by consolidating them into fewer, proportionally more valuable shares. (Beneficient executed a reverse stock split to reduce its authorized shares, potentially to meet exchange listing requirements or improve per-share metrics.)
- Warrant Shares
- Shares of common stock that can be purchased by a warrant holder at a specified price (exercise price) before the warrant expires. (Yorkville holds warrants for 165,674 shares at an exercise price of $21.04, indicating a potential future issuance of shares if the stock price appreciates significantly.)
- Selling Holders
- Existing shareholders who are registering their shares with the SEC to sell them in the public market. (The S-1 filing is primarily for the resale of shares by these holders, not for the company to raise capital.)
- Class A Common Stock
- The basic class of common stock issued by the company. (This is the primary equity security of Beneficient, with its trading price and authorized share count significantly impacted by recent events.)
Year-Over-Year Comparison
This S-1 filing focuses on the resale of existing shares and does not provide comparative financial data from a previous filing. Key events like the reverse stock split and the SEPA are new developments. Without prior financial statements or operational reports, a direct comparison of revenue growth, margin changes, or new risks relative to a prior period is not possible based on this information.
Filing Stats: 4,721 words · 19 min read · ~16 pages · Grade level 16.2 · Accepted 2025-12-22 22:01:57
Key Financial Figures
- $0.001 — ares of Class A common stock, par value $0.001 ("Class A common stock") of Beneficient
- $21.04 — A common stock at an exercise price of $21.04 we agreed to issue and sell to Yorkvill
- $250 million — eed to purchase from the Company, up to $250 million of the Company's shares of Class A comm
- $9.3 million — for an aggregate price of approximately $9.3 million. On June 20, 2024, the Company received
- $240.7 million — 27, 2023 under the SEPA. Approximately $240.7 million remains available under the SEPA. We ar
- $6 — 000,000. Assuming a (i) Market Price of $6.85, the closing price of our Class A co
- $4.0 m — an aggregate principal amount of up to $4.0 million, which will be convertible into s
- $2.0 million — kville purchased and the Company issued $2.0 million in aggregate principal amount of Conver
- $21 — A common stock at an exercise price of $21.04, which shall be exercisable into Cla
- $6.85 — s price of the Class A common stock was $6.85 per share, and the last reported sales
- $0.0137 — sales price of our Public Warrants was $0.0137 per Public Warrant. We are an "emerging
- $800.00 — t a rate based on a 20% discount to the $800.00 valuation of the Class A common stock (
- $640.00 — luation of the Class A common stock (or $640.00). As a result, in the Conversion, we is
Filing Documents
- forms-1.htm (S-1) — 10668KB
- ex5-1.htm (EX-5.1) — 33KB
- ex10-46.htm (EX-10.46) — 408KB
- ex10-47.htm (EX-10.47) — 407KB
- ex10-48.htm (EX-10.48) — 409KB
- ex10-49.htm (EX-10.49) — 411KB
- ex23-1.htm (EX-23.1) — 4KB
- ex107.htm (EX-FILING FEES) — 69KB
- pg157_01.jpg (GRAPHIC) — 126KB
- pg158_01.jpg (GRAPHIC) — 129KB
- formposam_001.jpg (GRAPHIC) — 4KB
- formposam_002.jpg (GRAPHIC) — 83KB
- formposam_003.jpg (GRAPHIC) — 27KB
- formposam_004.jpg (GRAPHIC) — 91KB
- formposam_0002.jpg (GRAPHIC) — 2KB
- formposam_0003.jpg (GRAPHIC) — 2KB
- formposam_0004.jpg (GRAPHIC) — 2KB
- pg171-200_001.jpg (GRAPHIC) — 100KB
- pg171-200_002.jpg (GRAPHIC) — 140KB
- pg171-200_003.jpg (GRAPHIC) — 192KB
- pg171-200_004.jpg (GRAPHIC) — 181KB
- pg171-200_007.jpg (GRAPHIC) — 156KB
- pg171-200_008.jpg (GRAPHIC) — 95KB
- pg171-200_009.jpg (GRAPHIC) — 238KB
- pg171-200_010.jpg (GRAPHIC) — 167KB
- pg171-200_011.jpg (GRAPHIC) — 61KB
- ex5-1_001.jpg (GRAPHIC) — 6KB
- ex10-46_001.jpg (GRAPHIC) — 34KB
- ex10-46_002.jpg (GRAPHIC) — 5KB
- ex10-47_002.jpg (GRAPHIC) — 5KB
- ex10-47_001.jpg (GRAPHIC) — 34KB
- ex10-49_001.jpg (GRAPHIC) — 34KB
- ex10-49_002.jpg (GRAPHIC) — 5KB
- 0001493152-25-028891.txt ( ) — 38803KB
- benf-20250930.xsd (EX-101.SCH) — 161KB
- benf-20250930_cal.xml (EX-101.CAL) — 115KB
- benf-20250930_def.xml (EX-101.DEF) — 768KB
- benf-20250930_lab.xml (EX-101.LAB) — 1010KB
- benf-20250930_pre.xml (EX-101.PRE) — 846KB
- forms-1_htm.xml (XML) — 6354KB
- ex107_htm.xml (XML) — 13KB
USE OF PROCEEDS
USE OF PROCEEDS 75 MARKET INFORMATION FOR COMMON STOCK AND DIVIDEND POLICY 75
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 76
BUSINESS
BUSINESS 141 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 177
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 187 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 207
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 237
DESCRIPTION OF SECURITIES
DESCRIPTION OF SECURITIES 241 SELLING STOCKHOLDERS 284 PLAN OF DISTRIBUTION 295 LEGAL MATTERS 300 EXPERTS 300 WHERE YOU CAN FIND ADDITIONAL INFORMATION 300 INDEX TO FINANCIAL STATEMENTS F-1 i ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 that we filed with SEC using a "shelf" registration process. The Selling Holders may, from time to time, sell the securities described in this prospectus. You should rely only on the information provided in this prospectus, as well as the information incorporated by reference into this prospectus and any applicable prospectus supplement. Neither we nor the Selling Holders have authorized anyone to provide you with different information. Neither we nor the Selling Holders have authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus or any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. Neither we nor the Selling Holders take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. You should not assume that the information in this prospectus or any applicable prospectus supplement is accurate as of any date other than the date of the applicable document. Since the date of this prospectus and the documents incorporated by reference into this prospectus, our business, financial condition, results of operations and prospects may have changed. Neither we nor the Selling Holders will make an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. We may also provide a prospectus supplement or post-effective amendment to the registration statement to add information to, or update or change information contained in, this prospectus. You should read both this prospectus and any applicable prospectus supplement or post-e